Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

95.25 -0.41 (-0.43%)
Streaming Delayed Price Updated: 9:58 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,497
Open 95.07
Bid (Size) 94.65 (100)
Ask (Size) 95.85 (300)
Prev. Close 95.66
Today's Range 93.80 - 95.67
52wk Range 36.36 - 120.74
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Down Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares o... 
Via StockStory

Performance

YTD
-6.4%
-6.4%
1 Month
+4.6%
+4.6%
3 Month
-11.1%
-11.1%
6 Month
-1.3%
-1.3%
1 Year
+136.7%
+136.7%

More News

Read More
News headline image
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Via StockStory
Topics Earnings
News headline image
Guardant Health (GH) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗
Via Chartmill
News headline image
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
Via StockStory
News headline image
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars
Via StockStory
News headline image
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Earnings: What To Look For From GH
Via StockStory
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
Via StockStory
Topics Government Stocks
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Via StockStory
News headline image
Why Is Guardant Health (GH) Stock Soaring Today
Via StockStory
Topics Government Stocks
News headline image
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Falling Today
Via StockStory
Topics Artificial Intelligence Economy Government
News headline image
3 Growth Stocks We Think Twice About
Via StockStory
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
Via MarketMinute
Topics Supply Chain
News headline image
3 Reasons to Avoid GH and 1 Stock to Buy Instead
Via StockStory
Topics Supply Chain
News headline image
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
From Guardant Health, Inc.
Via Business Wire
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 95.25
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 05/19/26 09:58 AM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 9.65B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.